Breaking News
Close
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product

Stock MarketsMay 13, 2022 16:10
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product

Here's a roundup of top developments in the biotech space over the last 24 hours:

Stocks In Focus Switzerland Approves Moderna (NASDAQ:MRNA)'s COVID-19 Shot For Kids 6-11 The Swiss drug regulatory authority has approved Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine for children ages 6-11.

The approval is for the vaccine's two-dose series of 50 micrograms per dose, Moderna added.

Shares were up 6.72% at $138.92 Friday.

Neurocrine's Huntington's Candidate Secures FDA Orphan Drug Tag

The FDA has granted Orphan Drug Designation to Neurocrine Biosciences Inc's (NASDAQ: NBIX) valbenazine for Huntington's disease (HD).

The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation.

Valbenazine is a selective vesicular monoamine transporter 2 inhibitor being investigated as a once-daily treatment in adults with chorea associated with HD.

Editas Gene-Editing Thalassemia Treatment Gets FDA Orphan Drug Status Editas Medicine Inc's (NASDAQ: EDIT) EDIT-301, an investigational gene-editing medicine for beta-thalassemia, has received FDA Orphan Drug Designation.

The FDA previously granted Rare Pediatric Disease designation to EDIT-301 for beta-thalassemia and sickle cell disease.

EDIT-301 is being investigated in a clinical study in severe sickle cell disease patients. Editas expects to initiate a Phase 1/2 study of EDIT-301 in patients with transfusion-dependent beta-thalassemia in 2022.

CSL's Vifor Buyout Hits Regulatory Delay CSL Ltd's (OTC: CSLLY) $11.7-billion buyout of Vifor Pharma AG (OTC: GNHAY) will have to wait a few more months.

While CSL previously expected to close the acquisition this June, the regulatory approval process is taking longer than expected. Some antitrust authorities have approved the transaction, but others remain outstanding, Vifor said in a statement.

Bristol Myers Sells New York Biologics Facility LOTTE Corporation has agreed to purchase Bristol Myers Squibb Co's (NYSE: BMY) manufacturing facility in East Syracuse, New York.

The East Syracuse site will serve as the LOTTE Center for North America Operations for LOTTE's new biologics contract development and manufacturing organization business in the U.S.

The companies anticipate completing the transaction by the second half of 2022.

Deal terms were not disclosed.

Statera Biopharma, Lay Sciences Ink License Pact For IgY Products Statera Biopharma (NASDAQ: STAB) intends to enter into a non-binding term sheet for a strategic partnership with Lay Sciences Inc to license worldwide manufacturing rights to certain Lay Sciences' IgY products containing avian antibodies as an active ingredient.

Lay Sciences would receive an upfront payment including equity and cash and would also have the potential to earn royalties and milestones associated with the development of IgY in gastrointestinal and upper respiratory indications.

Specific deal terms were not disclosed.

Shares were up 19.4% at 27 cents during the premarket session.

BridgeBio Pharma Sells Priority Review Voucher For $110M BridgeBio Pharma Inc (NASDAQ: BBIO) has agreed to sell its rare pediatric disease Priority Review Voucher for $110 million to an undisclosed purchaser.

BridgeBio was awarded the voucher when its affiliate, Origin Biosciences Inc., received approval of Nulibry (fosdenopterin) for injection as the first therapy to reduce the mortality risk in patients with molybdenum cofactor deficiency Type-A.

BridgeBio has amended its existing senior secured credit facility, extending the interest-only period by two years and principal repayment to Nov. 17, 2026.

Lantheus Starts Dosing In Imaging Agent Study to Monitor PD-L1 Expression In Lung Cancer Patients Lantheus Holdings Inc (NASDAQ: LNTH) has dosed the first patient in a Phase 2 trial evaluating NM-01 for its potential to identify patients who will respond to checkpoint inhibitor therapies.

NM-01 is a technetium 99m SPECT imaging agent used to assess PD-L1 expression in cancer cells.

Shares are rising 7.67% at $64.17 during the premarket session.

PolarityTE Shares Jump On FDA's RMAT Tag For SkinTE The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PolarityTE Inc's (NASDAQ: PTE) SkinTE under the company's open IND.

RMAT designation is a dedicated program designed to expedite the drug development and review processes for promising regenerative medicine products.

Shares are up 42.9% at 21 cents during the premarket session.

On The Radar Earnings The earnings list presented is not comprehensive. Click here to access Benzinga's earnings calendar for the complete schedule.

PLx Pharma Inc (NASDAQ: PLXP): Before Market Open.

Better Therapeutics Inc (NASDAQ: BTTX): Before Market Open.

Biofrontera Inc (NASDAQ: BFRI): Before Market Open.

ProPhase Labs Inc (NASDAQ: PRPH): Before Market Open.

Longeveron Inc (NASDAQ: LGVN): Before Market Open.

EQRx Inc (NASDAQ: EQRX): Before Market Open.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
 

Related Articles

Danone doubles supply of some baby formula to U.S.
Danone doubles supply of some baby formula to U.S. By Reuters - May 25, 2022

By Richa Naidu LONDON (Reuters) - Danone SA (EPA:DANO) on Wednesday said it has been doubling shipments to the United States of Neocate formula for infants allergic to cow's...

UK stocks edge higher, M&S slides on gloomy outlook
UK stocks edge higher, M&S slides on gloomy outlook By Reuters - May 25, 2022

(Reuters) - London's blue-chip index rose on Wednesday as the global mood steadied after a selloff a day earlier on slowdown worries, while Marks & Spencer slid after warning...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Our Apps
DOWNLOAD APPApp store
Investing.com
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
  • Sign up for FREE and get:
  • Real-Time Alerts
  • Advanced Portfolio Features
  • Personalized Charts
  • Fully-Synced App
Continue with Google
or
Sign up with Email